Extending Dosing Intervals in Retinal Disease: Patient Perspectives and Clinical Insights to Guide Your Practice

Neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME) are increasingly prevalent retinal diseases that pose significant challenges in ophthalmic care. While anti-vascular endothelial growth factor (VEGF) therapies have greatly improved visual outcomes for patients with these conditions, real-world data indicate that many patients receive suboptimal treatment and monitoring, resulting in poorer visual outcomes. Newer therapeutic options have been developed to extend treatment intervals and improve adherence. In DME, anti-VEGF therapies have demonstrated superior efficacy compared with laser photocoagulation, with newer agents offering the potential for longer-lasting effects. The evolving landscape of nAMD and DME treatment underscores the need for ongoing education to ensure that healthcare providers can integrate the latest clinical evidence into practice effectively. In this CE activity, expert faculty review anti-VEGF therapies that reduce treatment burden as well as recognize when patients are experiencing suboptimal response and adverse effects. They also assess best practices for referral and overall management of patients with retinal diseases.